

Sanja Dacic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9190804/publications.pdf>

Version: 2024-02-01

125
papers

13,437
citations

47006

47
h-index

22832

112
g-index

126
all docs

126
docs citations

126
times ranked

13961
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2015 World Health Organization Classification of Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1243-1260.	1.1	3,313
2	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013, 8, 823-859.	1.1	792
3	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	1.1	589
4	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346.	2.5	586
5	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 89-108.	2.5	461
6	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	1.1	429
7	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	9.4	422
8	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 828-860.	2.5	415
9	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	1.1	408
10	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 415-453.	2.8	397
11	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159.	2.8	241
12	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	1.1	234
13	Overexpression of Dicer in Precursor Lesions of Lung Adenocarcinoma. <i>Cancer Research</i> , 2007, 67, 2345-2350.	0.9	230
14	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. <i>Modern Pathology</i> , 2012, 25, 1574-1583.	5.5	206
15	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	1.1	205
16	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	1.1	203
17	Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. <i>Modern Pathology</i> , 2008, 21, 742-747.	5.5	188
18	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8001-8001.	1.6	176
20	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2010, 28, 5294-5300.	1.6	132
21	miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Modern Pathology, 2010, 23, 1577-1582.	5.5	129
22	The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Modern Pathology, 2016, 29, 14-24.	5.5	114
23	The Diagnostic Utility of p16 FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial Proliferations. American Journal of Clinical Pathology, 2011, 135, 619-627.	0.7	112
24	Significance of EGFR Protein Expression and Gene Amplification in Non-Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2006, 125, 860-865.	0.7	110
25	Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 627-635.	2.8	106
26	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	1.1	106
27	Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Modern Pathology, 2010, 23, 159-168.	5.5	105
28	Molecular Pathogenesis of Pulmonary Carcinosarcoma as Determined by Microdissection-Based Allelotyping. American Journal of Surgical Pathology, 2002, 26, 510-516.	3.7	104
29	MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Modern Pathology, 2020, 33, 245-254.	5.5	101
30	CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Modern Pathology, 2010, 23, 531-538.	5.5	93
31	Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas. Archives of Pathology and Laboratory Medicine, 2018, 142, 1549-1553.	2.5	87
32	Adenosquamous Carcinoma of the Lung. American Journal of Clinical Pathology, 2011, 135, 783-789.	0.7	82
33	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Human Pathology, 2010, 41, 94-102.	2.0	81
34	Adequacy of Core Needle Biopsy Specimens and Fine-Needle Aspirates for Molecular Testing of Lung Adenocarcinomas. American Journal of Clinical Pathology, 2015, 143, 193-200.	0.7	79
35	Malignant mesothelioma in situ: morphologic features and clinical outcome. Modern Pathology, 2020, 33, 297-302.	5.5	79
36	Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncology, 2021, 17, 4045-4055.	2.4	76

#	ARTICLE	IF	CITATIONS
37	<i>ALK</i> FISH patterns and the detection of <i>ALK</i> fusions by next generation sequencing in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 82943-82952.	1.8	69
38	Revolution in Lung Cancer: New Challenges for the Surgical Pathologist. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 110-116.	2.5	69
39	Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections. <i>Modern Pathology</i> , 2015, 28, 1058-1063.	5.5	67
40	Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 933-958.	2.5	65
41	The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2022, 17, 608-622.	1.1	64
42	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. <i>Modern Pathology</i> , 2016, 29, 735-742.	5.5	58
43	Postoperative fluorescence bronchoscopic surveillance in non-small cell lung cancer patients. <i>Annals of Thoracic Surgery</i> , 2001, 71, 967-970.	1.3	54
44	Patterns of Allelic Loss of Synchronous Adenocarcinomas of the Lung. <i>American Journal of Surgical Pathology</i> , 2005, 29, 897-902.	3.7	53
45	KRAS mutant allele-specific imbalance in lung adenocarcinoma. <i>Modern Pathology</i> , 2011, 24, 1571-1577.	5.5	53
46	The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. <i>Human Pathology</i> , 2017, 67, 160-168.	2.0	50
47	Malignant mesothelioma <i>in situ</i>. <i>Histopathology</i> , 2018, 72, 1033-1038.	2.9	50
48	EGFR Assays in Lung Cancer. <i>Advances in Anatomic Pathology</i> , 2008, 15, 241-247.	4.3	49
49	Fluorescence bronchoscopic surveillance after curative surgical resection for non-small-cell lung cancer. <i>Annals of Surgical Oncology</i> , 2000, 7, 176-180.	1.5	46
50	Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification. <i>Cancer Cytopathology</i> , 2013, 121, 629-637.	2.4	44
51	Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. <i>Modern Pathology</i> , 2017, 30, 329-339.	5.5	43
52	Immunohistochemical Profile of Cystosarcoma Phyllodes of the Breast: A Study of 23 Cases. <i>Breast Journal</i> , 2002, 8, 376-381.	1.0	41
53	Significance of EGFR Protein Expression and Gene Amplification in Non-Small Cell Lung Carcinoma. <i>American Journal of Clinical Pathology</i> , 2005, 125, 860-865.	0.7	40
54	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	1.1	40

#	ARTICLE	IF	CITATIONS
55	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	1.1	40
56	Pleural mesothelioma classification update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 59-72.	2.8	40
57	Loss of Heterozygosity Patterns of Sclerosing Hemangioma of the Lung and Bronchioloalveolar Carcinoma Indicate a Similar Molecular Pathogenesis. <i>Archives of Pathology and Laboratory Medicine</i> , 2004, 128, 880-884.	2.5	37
58	Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. <i>Journal of Clinical Pathology</i> , 2013, 66, 870-874.	2.0	36
59	Pulmonary Preneoplasia. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1073-1078.	2.5	36
60	Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. <i>Cancer Cytopathology</i> , 2020, 128, 126-132.	2.4	35
61	Targeted Therapies in Lung Cancer. <i>Surgical Pathology Clinics</i> , 2010, 3, 71-82.	1.7	33
62	KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. <i>Modern Pathology</i> , 2014, 27, 262-270.	5.5	32
63	<i>KRAS</i> mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma. <i>Histopathology</i> , 2018, 73, 207-214.	2.9	32
64	Molecular Diagnostics of Lung Carcinomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 622-629.	2.5	30
65	Small-cell neuroendocrine carcinoma displays unique profiles of tumor-suppressor gene loss in relationship to the primary site of formation. <i>Human Pathology</i> , 2002, 33, 927-932.	2.0	29
66	Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. <i>Neoplasia</i> , 2015, 17, 817-825.	5.3	29
67	Cytopathology of pulmonary adenocarcinoma with a single histological pattern using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification. <i>Cancer Cytopathology</i> , 2015, 123, 306-317.	2.4	28
68	Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples. <i>Advances in Anatomic Pathology</i> , 2018, 25, 24-30.	4.3	28
69	Morphologic and Clinicopathologic Features of Lung Squamous Cell Carcinomas Expressing <i>Sox2</i> . <i>American Journal of Clinical Pathology</i> , 2012, 138, 712-718.	0.7	27
70	Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. <i>Histopathology</i> , 2016, 68, 729-737.	2.9	26
71	Pleural mesothelioma classification "update and challenges. <i>Modern Pathology</i> , 2022, 35, 51-56.	5.5	26
72	Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 24063-24076.	1.8	26

#	ARTICLE	IF	CITATIONS
73	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021, 53, 446-453.	0.6	25
74	EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. <i>Human Pathology</i> , 2010, 41, 1053-1060.	2.0	24
75	RET Rearrangements in Lung Adenocarcinoma and Radiation. <i>Journal of Thoracic Oncology</i> , 2014, 9, 118-120.	1.1	23
76	Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 353-357.	2.5	22
77	Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. <i>Modern Pathology</i> , 2020, 33, 255-262.	5.5	22
78	Correlation of Cytomorphology and Molecular Findings in EGFR+, KRAS+, and ALK+ Lung Carcinomas. <i>American Journal of Clinical Pathology</i> , 2014, 141, 420-428.	0.7	21
79	Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 34.	5.0	21
80	Histopathologic and molecular approach to staging of multiple lung nodules. <i>Translational Lung Cancer Research</i> , 2017, 6, 540-549.	2.8	19
81	Present and Future Molecular Testing of Lung Carcinoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 94-99.	4.3	18
82	Lung Cancer and the Future of Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 293-295.	2.5	18
83	Minimally Invasive Adenocarcinomas of the Lung. <i>Advances in Anatomic Pathology</i> , 2009, 16, 166-171.	4.3	17
84	Testing for BAP1 loss and <i>CDKN2A/p16</i> homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. <i>Cancer Cytopathology</i> , 2020, 128, 939-947.	2.4	17
85	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. <i>Annals of the American Thoracic Society</i> , 2020, 17, 550-554.	3.2	17
86	Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 77-86.	3.1	16
87	Pros: the present classification of mucinous adenocarcinomas of the lung. <i>Translational Lung Cancer Research</i> , 2007, 6, 230-233.	2.8	15
88	Comparison of PD-L1 immunohistochemistry assays and response to PD-L1 inhibitors in advanced non-small cell lung cancer in clinical practice. <i>Histopathology</i> , 2019, 74, 269-275.	2.9	15
89	Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ. <i>Lung Cancer</i> , 2020, 149, 1-4.	2.0	14
90	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1477-1489.	2.5	14

#	ARTICLE	IF	CITATIONS
91	A comparison of <i>ALK</i> gene rearrangement and <i>ALK</i> protein expression in primary lung carcinoma and matched metastasis. <i>Histopathology</i> , 2017, 71, 269-277.	2.9	13
92	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	1.1	13
93	Histologic classification of idiopathic chronic interstitial pneumonias. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 29, S5-9.	2.9	13
94	Lung Carcinoma Morphology or Mutational Profile: That Is the Question. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1242-1243.	2.5	12
95	Malignant Mesothelioma In Situ: Clinical and Pathologic Implications. <i>Journal of Thoracic Oncology</i> , 2020, 15, 899-901.	1.1	12
96	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. <i>American Journal of Clinical Pathology</i> , 2021, 156, 989-999.	0.7	12
97	Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity. <i>Experimental and Molecular Pathology</i> , 2005, 78, 135-139.	2.1	11
98	Artificial intelligence (AI)-powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study. <i>Journal of Clinical Oncology</i> , 2021, 39, 106-106.	1.6	11
99	Microsatellite Instability Is Uncommon in Lymphoepithelioma-like Carcinoma of the Lung. <i>American Journal of Clinical Pathology</i> , 2007, 127, 282-286.	0.7	10
100	Dilemmas in Lung Cancer Staging. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1194-1197.	2.5	10
101	<i>FGFR1</i> Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status. <i>American Journal of Clinical Pathology</i> , 2016, 145, 55-61.	0.7	10
102	Reproducibility for histologic parameters in peritoneal mesothelioma. <i>Human Pathology</i> , 2017, 67, 54-59.	2.0	10
103	Deep-learning based classification distinguishes sarcomatoid malignant mesotheliomas from benign spindle cell mesothelial proliferations. <i>Modern Pathology</i> , 2021, 34, 2028-2035.	5.5	8
104	Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas. <i>Lung Cancer</i> , 2020, 143, 12-18.	2.0	7
105	HepPar-1 Expression in Primary Lung Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2013, 140, 225-230.	0.7	6
106	Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, e9-e10.	1.1	6
107	A Combination of MTAP and p16 Immunohistochemistry Can Substitute for <i>CDKN2A</i> Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 313-322.	2.5	6
108	Molecular Testing in Lung Carcinoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 7-9.	0.7	5

#	ARTICLE	IF	CITATIONS
109	Sex-determining region Y-box 2 amplification in preneoplastic squamous lesions of the lung. <i>Human Pathology</i> , 2013, 44, 706-711.	2.0	5
110	State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma. <i>Cytopathology</i> , 2022, 33, 57-64.	0.7	5
111	Molecular characterization of pleomorphic mesothelioma: a multi-institutional study. <i>Modern Pathology</i> , 2021, , .	5.5	3
112	Immunohistology of Lung and Pleural Neoplasms. , 2011, , 369-463.		2
113	Lung Carcinoma Staging Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 923-926.	2.5	2
114	Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e135-e136.	1.1	2
115	Solid papillary mesothelial tumor. <i>Modern Pathology</i> , 2021, , .	5.5	2
116	LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selipercatinib in patients with resectable stage IB-IIIa EGFR fusion-positive NSCLC. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8594-TPS8594.	1.6	2
117	Challenges in lung and thoracic pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1-3.	2.8	1
118	Molecular Prognostic Markers of Lung Cancer. <i>Molecular Pathology Library</i> , 2012, , 109-111.	0.1	1
119	Evaluation of Small Biopsy Material in Patients with Multiple and Secondary Tumors. , 2015, , 155-196.		1
120	Rebuttal from Professor Sanja Dacic. <i>Translational Lung Cancer Research</i> , 2007, 6, 241-242.	2.8	0
121	Pulmonary Pathology Integral to Clinical Decision Making. <i>Surgical Pathology Clinics</i> , 2010, 3, ix-x.	1.7	0
122	Molecular Aspects of Malignant Mesothelioma and Other Tumors of the Pleura and Peritoneum. , 0, , 106-114.		0
123	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting. <i>Translational Lung Cancer Research</i> , 2020, 9, 837-838.	2.8	0
124	Association of chromosome 17 copy number instability with favorable prognosis in nonsurgically treated gastroesophageal adenocarcinoma and impaired response to trastuzumab. <i>Journal of Clinical Oncology</i> , 2017, 35, 61-61.	1.6	0
125	The HGF-MET signaling pathway is enriched in LUAC brain metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, e20597-e20597.	1.6	0